Brooks Laboratories Ltd

Brooks Laboratories operates with a current liquidity position that is moderate, as indicated by a current ratio of 1.48, which is below the typical threshold of 2 for strong liquidity. The company's liquidity_fpt metric shows a net cash position that is negative after subtracting total debt, signaling potential short-term liquidity constraints. Profitability metrics for Brooks Laboratories are weak, with a return on equity (ROE) of -10.16% and a return on assets (ROA) of -8.06%. These figures are significantly below the industry median for pharmaceutical companies, which typically report positive ROE and ROA. The company's operating income of INR 34.25 million is also low relative to its revenue of INR 825.57 million, indicating poor margin performance. The company's revenue is concentrated in a single segment, "Pharmaceutical products, including ingredients and intermediaries," with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. Growth trajectory for Brooks Laboratories is uncertain, with a net loss of INR 99.67 million in the latest reporting period. The company's free cash flow is negative at INR -92.88 million, and capital expenditures are modest at INR -9.23 million. These figures suggest limited reinvestment in growth and operational capacity. Risk factors for Brooks Laboratories include a negative net income and a weak liquidity position. The company's debt-to-equity ratio of 0.08 is low, but the negative net cash position raises concerns about its ability to meet short-term obligations. There is no indication of dilution pressure in the near term, as shares outstanding remain stable. Recent events include the disclosure of a significant net loss and negative free cash flow in the latest financial filing. No major regulatory or operational events have been reported in the recent transcripts or filings.